Ocurrió un error. Detalles Ocultar
Usted tiene páginas sin guardar. Restablecer Cancelar

Biotechnology Innovation Organization

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Todos los conjuntos de datos:  B E V
  • B
    • febrero 2016
      Fuente: Biotechnology Innovation Organization
      Subido por: Knoema
      Acceso el: 03 mayo, 2016
      Seleccionar base de datos
      Sixth Biennial Report of Battelle and BIO indicate the followings:1. In 2012, U.S. bioscience companies employed 1.62 million personnel across more than 73,000 individual business establishments.2. Over the past decade the industry has added nearly 111,000 new, high-paying jobs or 7.4 percent to its employment base.3. The industry continues its tradition of creating high-wage, family-sustaining jobs with average wages 80 percent greater than the overall private sector and growing at a faster rate.
  • E
  • V
    • febrero 2016
      Fuente: Biotechnology Innovation Organization
      Subido por: Knoema
      Acceso el: 02 mayo, 2016
      Seleccionar base de datos
      Access to early-stage financing is the lifeblood of biotechnology innovation. For therapeutic-focused biotechnology companies in particular, the required capital and development timelines dwarf most other industries, making it challenging to find sizable early investments from committed investors. As the world’s largest trade association representing biotechnology companies across the United States and in more than 30 other nations, it is important for BIO to better understand investor trends in order to determine where scientific or policy issues may be impacting the ability to maintain a robust pipeline of innovative medicines.